FDA clears Atrium’s IND application to begin Corventis trial of ATR 1072

Atrium Therapeutics has received FDA clearance for its IND application to begin the Corventis Phase I/II trial of ATR 1072 for PRKAG2 syndrome. Atrium Therapeutics expects to enrol the first participant by the end of 2026. PRKAG2 syndrome is an autosomal dominant, early-onset cardiomyopathy, involving heart muscle thickening, conduction issues, and arrhythmias. Credit: NMK-Studio / Shutterstock.com. Atrium Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to begin the Corventis Phase I/II clinical trial of ATR 1072 for Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. The rare autosomal…

Source: Clinical Trials Arena